Reference information
■Pipeline of prescription pharmaceuticals (Clinical Stage)
A prostaglandin F2α derivative for the treatment of glaucoma and ocular hypertension. Launched in Japan in December, 2008. In Europe, launched in Germany,Denmark, etc. In the countries including the U.S., development rights were granted to Merck & Co., Inc. (U.S.) in April, 2009. In Asia, launched in Hong Kong,Korea, Indonesia, Singapore, etc. NDA filed in China.
A dry eye treatment drug which stimulates secretion of mucin and aqueous components from the corneal epithelium. Its mechanism of action is different fromother existing treatments. Launched in December, 2010 in Japan and in October, 2013 in Korea. NDA filed in China.
A new type of glaucoma treatment which inhibits the progression of visual field defects. It is the only calcium antagonist being development as an oral glaucomatreatment. Compared to NMDA receptor antagonists, it has excellent safety profile with mild systemic adverse drug reactions.
A microsphere product with a new drug delivery concept. Stable and sustained efficacy is expected with a local injection. Collaborating with OakwoodLaboratories (U.S.) for manufacturing technology development on commercial scale. *BRVO: Branch retinal vein occlusion.
An intravitreal injection with immunosuppressive effect, anti-angiogenic effect, etc. Phase 3 study is ongoing in the U.S., Japan and Europe.
A fixed dose combination drug of a prostaglandin F2α derivative and a beta-adrenergic receptor blocker. NDA filed in June, 2013 in Europe. Approved inSeptember, 2013 in Japan.
An H₁ receptor antagonist with membrane-stabilizing function, as treatment for allergic conjunctivitis. Launched in November, 2013 in Japan.
EP2 receptor agonist with a new mechanism of action. Preparation of Phase 2b in the U.S. Reference information
■Pipeline of prescription pharmaceuticals (Clinical Stage)
A prostaglandin F2α derivative for the treatment of glaucoma and ocular hypertension. Preservative-free, unit-dose type product. Launched in October, 2013 in Japan.
An intravitreal injection with dual inhibitor of VEGF and PDGF. Started on Phase 1/2a in January, 2014 in U.S.
A joint injection inducing apoptosis in diseased joints of rheumatoid arthritis patients. Next development plan is under evaluation based on Phase 2 study results.
■Santen S.A.S. pipeline of prescription pharmaceuticals (Clinical Stage)
An ophthalmic emulsion which improves symptoms and signs of severe dry eye by immunosuppressive effect. Cationicemulsion technology has enhanced ocular tissue absorption.
An ophthalmic emulsion which improves symptoms of vernal keratoconjunctivitis by immunosuppressive effect. Cationicemulsion technology has enhanced ocular tissue absorption.
An ophthalmic emulsion of a prostaglandin F2α derivative, for the treatment of glaucoma and ocular hypertension.
An intravitreal injection with anti-inflammatory effect.
*Catioprost and Cortiject are under project evaluation.
■Changes from 2Q FY13 (November 6, 2013)
Launched as Alesion Ophthalmic Solution in November, 2013 (Japan)
Started on Phase 1/2a in January, 2014 (U.S.)
MINUTES OF THE REGULAR SCHOOL BOARD MEETING OF THE RIVER RIDGE BOARD OF EDUCATION OF THE RIVER RIDGE SCHOOL DISTRICT, GRANT COUNTY, WISCONSIN: February 11, 2013 The Regular Meeting of the River Ridge Board of Education was called to order by President Bill Mergen on Monday, February 11, 2013, at 6:00 p.m. Roll call was taken with the following Also present were District Administrator Lee Pritzl
Piedmont Orthopedic Society ABSTRACTS 1999 1999 The Management of Equinus Deformity in Cerebral Palsy J. Leonard Goldner, M.D., Duke University Medical Center, Box 3706, Durham, NC The patients were diagnosed and followed at Duke clinics, inpatient and outpatient units sponsored by the North Carolina Health Department and North Carolina Cerebral Palsy Hospital. Surgical treatment